# Imagion Biosystems

Source: https://onco.cc/companies/imagion-biosystems/  
OnCo record `imagion-biosystems` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Imagion Biosystems makes an MRI contrast agent of tiny magnetic particles that stick to a cancer marker, so a scan can show whether HER2-positive breast cancer has spread to the lymph nodes without a biopsy.

## Summary

Imagion Biosystems, Ltd., registered at Bourke Street, Melbourne, with a US subsidiary, Imagion Biosystems, Inc., in Incline Village, Nevada, develops MagSense molecular MRI: bio-safe magnetic nanoparticles linked to targeting molecules that bind cancer biomarkers. Its lead agent, the MagSense HER2 Imaging Agent (MSH2IA), completed a multi-site phase 1 study (enrolment closed in July 2023) in HER2-positive breast cancer to assess spread to axillary lymph nodes, and the company says it detects tumour signals as small as 1 to 2 mm; a folate receptor agent for ovarian cancer is preclinical. The company identifies itself as IBX and publishes ASX announcements. Its first registered cancer trial on ClinicalTrials.gov, NCT07885683, a phase 1b/2 study of MSH2IA with MRI in HER2-positive breast cancer, was posted in October 2026; no earlier study is registered on ClinicalTrials.gov under this sponsor name.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Imagion Biosystems, Ltd.; Imagion Biosystems, Inc.
- HQ: Melbourne
- Type: imaging
- Website: https://imagionbiosystems.com/
- Ticker: IBX

## Notes

- The ticker IBX and an ASX listing are inferred from the company's investor site, which lists 'ASX Announcements' and refers to the company as IBX; an exchange-and-ticker statement was not found in the text read. Founding year not stated. The 1 to 2 mm detection claim is the company's own. Read on 29 October 2026.

## Sources

- Official website: https://imagionbiosystems.com/
- Investor site: https://investor.imagionbiosystems.com/
- ClinicalTrials.gov: phase 1b/2 trial of MSH2IA (NCT07885683): https://clinicaltrials.gov/study/NCT07885683

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Imaging](https://onco.cc/fronts/imaging/)
- technologies: [MRI](https://onco.cc/technologies/mri/)
- targets: [HER2](https://onco.cc/targets/her2/)

---
JSON: https://onco.cc/api/v1/entities/imagion-biosystems.json